Skip to main content
. 2014 Oct 30;7(1):199–211. doi: 10.4161/19420862.2014.979081

Figure 6.

Figure 6.

Effect on Δψm and ROS. (A) Treatment of D1–1 cells with the Dried-I format of epratuzumab (hLL2*) induced a decrease in Δψm. (B) Treatment of Daudi cells with the Dried-II format (HUV-EC/hLL2) also induced a decrease in Δψm, similar to that observed with the Dried-I format (hLL2*). (C) Both the Dried-I (hLL2*) and the Dried-II (HUV-EC/hLL2) formats of epratuzumab increased the generation of ROS in Daudi cells.